BACKGROUND:Chronic kidney disease (CKD) is associated with an increased incidence of cardiovascular disease (CVD). A few studies have demonstrated elevated plasma adiponectin and leptin levels in CKD. The aims of this study were to assess whether 1) estimated glomerular filtration rate (eGFR) is associated with plasma leptin and adiponectin; and 2) adiponectin and leptin (partly) explain associations of CKD with endothelial dysfunction, insulin resistance, and low-grade inflammation in patients with K/DOQI Stage 3 - 5 CKD. METHODS: Baseline data from 91 patients with Stage 3 - 4 CKD in the anti-oxidant therapy in chronic renal insufficiency study, a randomized, double-blind, placebo-controlled trial, in which the effects of oxidative stress-lowering treatment on vascular function and structure were studied, and from 50 dialysis naïve patients, who took part in an open-label, randomized study that compared two peritoneal dialysis regimens, used in the analysis. All subjects for both the studies were recruited in the same centres. RESULTS: The association between eGFR and adiponectin was non-linear. In multivariate analysis, log-eGFR (unstandardized beta = 8.303 microg/ml, p < 0.0001) was the strongest determinant of adiponectin, and body mass index the strongest determinant of leptin (beta = 2.477 ng/ml, p < 0.0001). Plasma adiponectin and leptin did not modify the associations between eGFR and plasma von Willebrand factor or soluble vascular adhesion molecule-1. Plasma leptin had the strongest association with the homeostatic model assessment (HOMA-IR) index. Plasma C-reactive protein had no association with adiponectin or leptin. CONCLUSIONS: In patients with K/DOQI Stage 3 - 5 CKD, renal function had a significant non-linear inverse association with and was the strongest predictor of adiponectin. BMI was the strongest predictor of plasma leptin. Plasma adiponectin and leptin did not explain, and thus presumably are not involved in, the association between eGFR and some markers of endothelial dysfunction.
RCT Entities:
BACKGROUND:Chronic kidney disease (CKD) is associated with an increased incidence of cardiovascular disease (CVD). A few studies have demonstrated elevated plasma adiponectin and leptin levels in CKD. The aims of this study were to assess whether 1) estimated glomerular filtration rate (eGFR) is associated with plasma leptin and adiponectin; and 2) adiponectin and leptin (partly) explain associations of CKD with endothelial dysfunction, insulin resistance, and low-grade inflammation in patients with K/DOQI Stage 3 - 5 CKD. METHODS: Baseline data from 91 patients with Stage 3 - 4 CKD in the anti-oxidant therapy in chronic renal insufficiency study, a randomized, double-blind, placebo-controlled trial, in which the effects of oxidative stress-lowering treatment on vascular function and structure were studied, and from 50 dialysis naïve patients, who took part in an open-label, randomized study that compared two peritoneal dialysis regimens, used in the analysis. All subjects for both the studies were recruited in the same centres. RESULTS: The association between eGFR and adiponectin was non-linear. In multivariate analysis, log-eGFR (unstandardized beta = 8.303 microg/ml, p < 0.0001) was the strongest determinant of adiponectin, and body mass index the strongest determinant of leptin (beta = 2.477 ng/ml, p < 0.0001). Plasma adiponectin and leptin did not modify the associations between eGFR and plasma von Willebrand factor or soluble vascular adhesion molecule-1. Plasma leptin had the strongest association with the homeostatic model assessment (HOMA-IR) index. Plasma C-reactive protein had no association with adiponectin or leptin. CONCLUSIONS: In patients with K/DOQI Stage 3 - 5 CKD, renal function had a significant non-linear inverse association with and was the strongest predictor of adiponectin. BMI was the strongest predictor of plasma leptin. Plasma adiponectin and leptin did not explain, and thus presumably are not involved in, the association between eGFR and some markers of endothelial dysfunction.
Authors: Daniela Catalano; Guglielmo M Trovato; Giuseppe Fabio Martines; Clara Pirri; Francesca M Trovato Journal: Hepatol Int Date: 2011-01-28 Impact factor: 6.047
Authors: Adriana M Hung; Chutatip Limkunakul; Jenny S Placido; Edward D Siew; Charles D Ellis; Ayumi Shintani; Talat Alp Ikizler Journal: J Nephrol Date: 2014-03-08 Impact factor: 3.902
Authors: Maria P Martinez Cantarin; Scott W Keith; Scott A Waldman; Bonita Falkner Journal: Nephrol Dial Transplant Date: 2014-07-21 Impact factor: 5.992
Authors: Nihal Aydemir; Mindy M Pike; Aseel Alsouqi; Samuel A E Headley; Katherine Tuttle; Elizabeth E Evans; Charles M Milch; Kelsey A Moody; Michael Germain; Loren Lipworth; Jonathan Himmelfarb; T A Ikizler; Cassianne Robinson-Cohen Journal: Nutr Metab Cardiovasc Dis Date: 2020-04-21 Impact factor: 4.222
Authors: Ana Paula Bazanelli; Maria Ayako Kamimura; Maria Eugenia Fernandes Canziani; Silvia Regina Manfredi; Lilian Cuppari Journal: Perit Dial Int Date: 2012-09-01 Impact factor: 1.756
Authors: Maria P Martinez Cantarin; Scott A Waldman; Cataldo Doria; Adam M Frank; Warren R Maley; Carlo B Ramirez; Scott W Keith; Bonita Falkner Journal: Kidney Int Date: 2013-01-02 Impact factor: 10.612
Authors: A P Doumatey; J Zhou; H Huang; J Adeleye; W Balogun; O Fasanmade; T Johnson; J Oli; G Okafor; A Amoah; B Eghan; K Agyenim-Boateng; J Acheampong; C Adebamowo; A Adeyemo; C N Rotimi Journal: Int J Nephrol Date: 2012-08-22